Main Menu

Meet our scientists at upcoming industry collaboration events

A graphic with logos for IN-PART and the ICR, the text "What's at the cutting edge? Uncovering new immuno-oncology innovations at the ICR", and images of scientists Dr Esther Artwert, Dr Stephen Pettitt, and Dr Erik Wennerberg

Two upcoming events will give industry experts the chance to hear from some of our leading researchers about opportunities to work with them.

One gives potential partners the chance to meet our team leaders at the latest in our Partnering to Defeat Cancer networking series, as we visit Bristol for the first time for an industry partnering event at the Engine Shed innovation hub.

And before that we are spotlighting several opportunities to work with our scientists in projects relating to immuno-oncology, in an online global partnering event taking place next week.

Immuno-oncology online partnering event

The Institute of Cancer Research, London, is working with academia-business partnering company IN-PART to host the latest in their Global Challenges Virtual Series.

This online global partnering event will take place on Tuesday 28th February at 4pm (GMT) and will spotlight three ICR projects at the cutting-edge of immuno-oncology which are currently open for partnership.

Dr Esther Arwert, Functional Tumour Immunology Team Leader, is seeking a partner to continue the discovery and development of small molecule inhibitors of ERAP1, which could enhance the effectiveness of checkpoint inhibitors or radiotherapy.

Dr Stephen Pettitt, Deputy Team Leader of the Gene Function Team, is seeking partners to collaborate on the development of anti-cancer vaccines or immunotherapeutic approaches to help overcome drug resistance in certain solid tumours.

Meanwhile Dr Erik Wennerberg, Radiation-enhanced Immunotherapy Team Leader, is looking for an industrial partner to help advance research on targeting ART1 to overcome resistance to immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) treatment.

You can register to attend this online event by completing this online form.

Breakfast briefing – in-person event in Bristol

The ICR’s Business and Innovation Office, partnering with SETSquared, is also set to host an in-person business networking event on Thursday 23rd March, at The Engine Shed in Bristol from 9.30-1pm.

Attendees will hear quick-fire presentations from leading cancer researchers at the ICR showcasing their work before a panel discussion, a Q&A with our speakers and networking.

Speakers will include:

Professor Jessica Downs – Deputy Head of the ICR’s Division of Cancer Biology, an expert in chromatin and the interplay between epigenetics and genome stability in the context of cancer.

Dr Rachael Natrajan – our Functional Genomics Team Leader, Dr Natrajan is researching how different subgroups of breast cancer can be characterised through genetic analysis.

Professor Udai Banerji – Deputy Director of Drug Development at the ICR and our partner hospital, The Royal Marsden, Professor Banerji oversees a major cancer-focused early clinical trial units. At any one time, the Drug Development Unit at the ICR and The Royal Marsden is running around 50 first-in-human clinical trials of novel cancer drugs, many in collaboration with industry partners.

Professor Jeffrey Bamber – a leading expert in research to improve the use of ultrasound imaging in cancer medicine and research. His previous work on freehand strain imaging led to systems on commercial ultrasound elastography devices now used around the world.

Andy Carr – Andy is Business Development Manager at the ICR and will introduce a range of opportunities for companies to work with us to develop new cancer treatments and technologies. The event will conclude with a panel discussion, followed by Q&A and networking.

Read the full agenda and sign up to our Partnering to Defeat Cancer event via Eventbrite.

Future events

The ICR’s Business and Innovation Office regularly hosts and attends industry events. Keep up to date with upcoming events and news about our work with industry – including collaboration opportunities – by signing up to our Connections newsletter.


PARP inhibitors immunotherapy Stephen Pettitt Erik Wennerberg oncology industry collaboration partnering art1 esther artwert in-part immuno-oncology
comments powered by Disqus